Registry of Chinese Patients with Marginal Zone Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the real-world treatment approaches and their effectiveness and safety for Chinese patients diagnosed with marginal zone lymphoma. It aims to gather data on patient characteristics and assess health-related quality of life. Treatment regimens will be determined by physicians based on standard clinical practices and drug labels in China. The study will provide insights into how marginal zone lymphoma is managed in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be diagnosed as MZL
* Meet the treatment indications for MZL

Exclusion Criteria:

* Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Where it's running

• Shanghai Ruijin Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Weili Zhao
• Email: zwl_trial@163.com
• Phone: +862164370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

• Orelabrutinib for adults with early-stage untreated marginal zone lymphoma

  This trial will try orelabrutinib, a selective oral BTK inhibitor, as first-line treatment for adults with stage I–II marginal zone lymphoma to see if it works and is safe.

  Recruiting at 14 sites Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Guangzhou, Guangdong and 13 other locations · NCT07441993

• Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma

  This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07233720

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Reduced-dose radiation therapy for people with follicular or marginal zone lymphoma

  This trial will test whether very low-dose radiation controls stage I–II follicular or marginal zone lymphoma as well as standard-dose radiation while causing fewer side effects.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07029217

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.